The objective of our study is to investigate whether the substitution of the standard locking solution with a locking solution containing taurolidine and urokinase weekly (Taurolock ™ U 25,000 - www.taurolock.com ) reduces the rate of catheter dysfunction in hemodialysis patients with a history of TCC dysfunction requiring urokinase therapy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
68
Bracops Hospital
Anderlecht, Brussels Capital, Belgium
Ixelles Hospital
Ixelles-Elsene, Brussels Capital, Belgium
Brugman Hospital
Jette, Brussels Capital, Belgium
Universitair Ziekenhuis Brussel
Jette, Brussels Capital, Belgium
Requirement of Urokinase
Requirement of Urokinase for thrombotic malfunction of dialyse catheter
Time frame: 6 months
Removal of dialysis catheter
Removal of dialysis catheter for thrombosis and for bacteremia
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
CHU Charleroi
Charleroi, Hainaut, Belgium
CHWAPI
Tournai, Hainaut, Belgium
UZ Antwerpen
Antwerp, Belgium
Ixelles Hospital
Brussels, Belgium
Ghent Hospital
Ghent, Belgium